Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Thursday 30 April, 2020

Credit Suisse (Eur)

Post stabilisation notice-Fresenius SE & Co KGaA

RNS Number : 5657L
Credit Suisse Securities (Eur) Ltd
30 April 2020
 

30th April 2020

 

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

 

Fresenius SE & Co KGaA

 

Post-stabilisation Period Announcement

 

 

Further to the pre-stabilisation period announcement dated 31stMarch 2020, Credit Suisse Securities (Europe) Limited (contact: Dhiren Shah; telephone: +44 (0) 20 7888 0048 ) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

 

Issuer:

Fresenius SE & Co KGaA

Guarantor (if any):


Aggregate nominal amount:

EUR 750,000,000

Description:

Senior Notes Due 2027

Stabilisation Manager(s):

Credit Suisse Securities (Europe) Limited

Offer price:

99.021

 

Although stabilisation offers were made, no stabilisation transactions were carried out.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States. 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
STAZZGFDVGVGGZM

a d v e r t i s e m e n t